Pharmaceutical Technology

MAY 19, 2023

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. Rituximab biosimilars have since achieved notable commercial success, with global sales surpassing $900m collectively.

Sales 59

Sales Competition Marketing Patients 59

Pharmaceutical Technology

JULY 20, 2023

By 2029, RSV drugs are forecast to surpass $9bn in sales, This surge can be attributed to recent developments in preventative measures.

Marketing 40

Marketing Sales 40

Clarivate

JANUARY 8, 2024

Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. FDA accelerated approval in August, Clarivate projects the drug will see $850 million in sales by 2029. Granted U.S.

Marketing 59

Marketing Patients Healthcare Healthcare 59

Quantified

SEPTEMBER 21, 2023

through 2029. Part of that growth comes from using AI tools for professional work, especially sales. According to Gartner, 75% of B2B sales organizations will augment traditional playbooks with AI by 2025 despite the current low adoption rate. Competitive pressure will drive companies to invest in AI tools for sales.

Sales 52

Sales Prospecting Training Sales tools 52

Pharmaceutical Technology

MAY 12, 2023

BlissBio has the potential to earn up to $2bn in commercial milestone payments, as well as royalties on sales if Eisai exercises its option to license the drug. The drug became a blockbuster last year, with sales reaching $1.9bn, up from $599m in 2021. targeting ADC.

Sales 64

Sales Marketing 64

Pharmaceutical Technology

SEPTEMBER 23, 2022

It is expected to expire on 21 January 2029, with paediatric exclusivity lasting until 21 July 2029. Merck has also permitted the sale of generic versions of Janumet XR to the market in July 2026 or before. It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027.

Food and Drug Administration 69

Food and Drug Administration FDA Food Marketing 69

European Pharmaceutical Review

AUGUST 21, 2023

Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. GSK Furthermore, biopharma firm GSK reported +4 percent and +11 percent ex COVID sales in the second quarter of 2023. Drugs Verzenio, Jardiance and Taltz led this result.

Biopharma 98

Biopharma Marketing Sales Medicine 98

Pharmaceutical Technology

APRIL 24, 2023

According to GlobalData’s Pharma Intelligence Centre, a sales consensus forecasts Brukinsa to have global sales of $3.98 billion in 2029, while Calquence is expected to make $5.31 While Imbruvica sales were $3.78 billion in 2029. billion in the same year.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

Pharmaceutical Technology

JUNE 13, 2023

According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. GlobalData forecasts total sales from this drug class to exceed $1bn by 2029. It received fast track and breakthrough designation from the FDA and is poised to be first to market.

Patients 52

Patients Sales Competition Safety 52

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker.

Medical 143

Medical Prescription Management Manufacturing 143

European Pharmaceutical Review

JUNE 28, 2023

If commercialisation is successful, obicetrapib is expected to value $619 million in sales by 2029, stated GlobalData. According to GlobalData, the CETP inhibitor obicetrapib is in the pipeline for dyslipidaemia. The treatment is expected to launch in 2028 in the US, EU, and Japan. appeared first on European Pharmaceutical Review.

Patients 97

Patients Sales Medical Pharmaceutical 97

Pharmaceutical Technology

MAY 10, 2023

billion in global sales in 2029, while Truvada estimates amount to $30 million. Truvada has since gone generic, with Teva Pharmaceuticals launching the first FDA-approved Truvada generic in October 2020. According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Descovy is estimated to yield $1.83

Government 105

Government FDA Pharmaceutical Sales 105

European Pharmaceutical Review

JANUARY 18, 2024

In its report on the insomnia market published last month, GlobalData expected that sales for DORAs, which offer a new mechanism of action for the condition, will continue to grow at a CAGR of 8.6 million in sales by 2032. percent sales expected in 2032 within the seven major markets. percent between 2022 and 2032.

Marketing 98

Marketing Sales Pharmacology Pharma 98

pharmaphorum

NOVEMBER 18, 2022

Physician-scientist led biotech Regeneron will be responsible for funding preclinical and clinical development and commercialisation activities, while oncology-focused biopharma CytomX will receive $30 million in an upfront payment , with the potential for up to $2 billion in research, development, regulatory, and sales-based milestones, also.

Biopharma 92

Biopharma Physicians Sales Patients 92

pharmaphorum

SEPTEMBER 30, 2022

8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029. The two judgments are a big victory for Merck, given that Januvia remains its third best-selling product after cancer immunotherapy Keytruda (pembrolizumab) and HPV vaccine Gardasil, with sales of almost $2.5

Marketing 59

Marketing Sales Competition FDA 59

Pharmaceutical Technology

MAY 23, 2023

According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Lumakras, also known as sotorasib, has projected sales of $1.47 billion in 2029. In May 2021, Amgen’s Lumakras was approved for use in adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Sales 52

Sales Pharma Pharmaceutical Patients 52

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. million by 2029. Novo Nordisk reported an 18.2%

Marketing 52

Marketing Sales Pharma Leads 52

Pharmaceutical Technology

JANUARY 10, 2023

billion in sales in 2019, increasing to $136.2 billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Mounjaro is forecast to compete for significant market share with semaglutide and also Lilly’s Trulicity (dulaglutide), reaching peak sales of $10.2

Marketing 52

Marketing Physicians Leads Sales 52

pharmaphorum

OCTOBER 26, 2022

First approved back in 2014, it is still growing strongly, with its 2021 sales of €2.5 Ofev is, however, heading for patent expiry in 2029, and Boehringer is looking to BI 1015550 to maintain the franchise beyond that date, and also to improve the treatment of IPF, which remains incurable.

Recruitment 95

Recruitment Prospecting Marketing Patients 95

Pharmaceutical Technology

JULY 8, 2022

Blincyto has provided a strong positive signal to demonstrate the clinical and commercial viability of BiTEs, with 2021 company-reported global sales of $542 million and GlobalData’s analyst consensus forecast projecting peak annual sales of $771 million by 2029, thereby sparking further industry interest in this field.

Safety 59

Safety Sales Marketing Patients 59

pharmaphorum

NOVEMBER 24, 2022

Despite J&J’s high hopes for the drug, sales have remained low, not warranting a mention in any of J&J’s quarterly financial updates since launch, and the company will look to the new data to try to encourage take-up. .

Sales 52

Sales Patients Competition Marketing 52

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

FEBRUARY 3, 2023

According to GlobalData’s Sales and Forecast Consensus database, Humira is anticipated to have garnered sales of $18.6 Based on GlobalData’s patient-based forecast models, RA and CD are the top two indications contributing to this value, accounting for around 45% and 14%, respectively, of Humira’s sales. billion in 2022.

Marketing 52

Marketing Sales Patients Management 52

pharmaphorum

DECEMBER 20, 2022

Wedbush Securities recently forecast more than $1 billion in 2029 sales for ensifentrine in the US alone, assuming a launch in the first quarter of 2024, and said today the stock could easily reach $30. Shares in Verona popped on the news, rising more than 40% to approach $19.50 and drive the company’s market cap to almost $1.5

Pharma 59

Pharma Sales Leads Marketing 59

Pharmaceutical Technology

APRIL 4, 2023

According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 billion in 2029. Tagrisso was approved for use as a first-line treatment for metastatic NSCLC with EGFR mutation in April 2018. GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

MedTechVets

SEPTEMBER 23, 2020

Bureau of Labor Statistics, the demand for clinical laboratory technologists and technicians will increase 7% from 2019 to 2029, “ faster than the average for all occupations.” As interest in developing better medical devices pique, so does the need for medical device sales managers. The Projections. According to a 2019 U.S.

Sales Management 52

Sales Management Medical Management Engineering 52

Pharmaceutical Technology

JULY 15, 2022

Over the next few years, biosimilars are expected to erode the sales of major originator insulin brands such as Sanofi’s Lantus (insulin glargine), Eli Lilly’s Humalog, and Novo Nordisk’s NovoLog. GlobalData is the parent company of Pharmaceutical Technology. Industry split over the pricing issues.

Manufacturing 131

Manufacturing Insurance Pharmaceutical Marketing 131

PM360

APRIL 7, 2023

Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.”

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Spotio

MAY 7, 2024

There’s never been a better time to be in telecom sales. billion in the US alone by 2029. In other words, there’s plenty of opportunity—as long as you know how to generate telecom sales leads effectively, of course. Building ICPs for your sales team will keep your reps focused. The result?

Leads 52

Leads Sales Prospecting Distribution 52

Pharmaceutical Technology

MAY 17, 2023

According to consensus forecasts from GlobalData’s Pharma Intelligence Centre, Ocaliva is forecasted to have global sales of $1.08 billion in 2029. The condition gradually worsens and can result in liver failure. GlobalData is the parent company of Pharmaceutical Technology.

Food and Drug Administration 52

Food and Drug Administration FDA Pharmaceutical Prospecting 52